Viagra: is it an effective treatment for stillbirth (STRIDER)

Viagra works by increasing blood flow. Fetal growth restriction is often caused by poor flow of blood through the placenta. This trial is looking at whether Viagra is effective in increasing blood flow to the baby.

  • Authors list

    Dr Elizabeth Cottrell, Dr Sarah Finn-Sell, Dr Mark Dilworth, Dr Sue Greenwood, Dr Mark Wareing, Professor Philip Baker, Professor Sandy Davidge, Professor Colin Sibley

This study is now complete. 

Several drugs already in use have potential as treatments for pre-eclampsia and fetal growth restriction, by improving blood flow in the placenta. This means that it is easier for the baby to get the food and oxygen it needs in the womb.

We studied some of these drugs in mice, to find out how well they work and to make sure they are safe for use in pregnancy. We found that sildenafil (better known by its brand name Viagra), improves the function of blood vessels taken from human placentas. We have also shown in a small study in Canada that Viagra improves the growth of babies with FGR.

Based on the results of this small study, the Medical Research Council has provided £3m to fund a multi-centre clinical trial of Viagra for the treatment of FGR. The Manchester Placenta Clinic is playing a major role in this study, and we hope that it will pave the way for effective treatments for fetal growth restriction.

The UK study finished recruitment ahead of schedule this year, which is almost unprecedented in this sort of study. This was mainly due to our Placenta Clinic, which recruited 41 women out of a total of 126 nationwide.

Get our research updates

Tommy's funds research across the UK investigating the reasons for pregnancy complications and loss. We can keep you updated on our research news.  If you're interested in being kept updated about our research and news from Tommy's, click here.

This study takes place in a Tommy's centre and is funded by the Medical Research Council

More research projects

  • Research into stillbirth

    When a baby dies after 24 weeks of gestation, it is called a stillbirth. Nearly 3000 families a year get the devastating news that their baby is not alive. Our research is helping to change this.
    Research into stillbirth

  • Understanding the causes of stillbirth by studying the placenta

    We still don’t know enough about the changes in the placenta which lead to stillbirth. Our researchers are using cutting-edge techniques to find out more.
    Understanding the causes of stillbirth by studying the placenta

  • The AFFIRM trial for prevention of stillbirth

    Researchers supported by Tommy’s are looking at whether a package of care and resources for pregnant women can help stop stillbirths.
    The AFFIRM trial for prevention of stillbirth

  • MiNESS – is there a link between stillbirth and a woman’s position going to sleep?

    A study led by Professor Alex Heazell at the Tommy’s Stillbirth Research Centre at St Mary’s Hospital, Manchester, investigated the link between stillbirth and a woman’s sleeping pattern.
    MiNESS – is there a link between stillbirth and a woman’s position going to sleep?

  • Diabetes, fetal growth and stillbirth

    Women suffering from type 1 or type 2 diabetes are more likely to suffer from stillbirths. We want to help people with diabetes to have healthy pregnancies.
    Diabetes, fetal growth and stillbirth

  • Preventing stillbirth: the role of the immune system in rejecting the placenta

    Tommy’s are studying chronic histiocytic intervillositis, which causes the immune system to reject the placenta, leading to stillbirth or miscarriage.
    Preventing stillbirth: the role of the immune system in rejecting the placenta

  • Can low levels of taurine make stillbirth more likely?

    Tommy’s researchers are looking at how the lack of an important nutrient might harm the placenta during pregnancy, putting women at a higher risk of stillbirth.
    Can low levels of taurine make stillbirth more likely?

  • Understanding how the womb lining matures during pre-eclampsia

    Pre-eclampsia can lead to health problems and sometimes stillbirth, but we don’t know enough about what causes it. Our researchers are studying how the lining of the womb develops during early pregnancy. This could reveal new ways to prevent pre-eclampsia and reduce the risk of stillbirth.
    Understanding how the womb lining matures during pre-eclampsia

  • Homing peptides: targeting drugs to the placenta

    Drugs which could help prevent pregnancy complications can’t reach the placenta effectively. Tommy’s researchers are making use of ‘homing peptides’ to deliver drugs directly to the placenta. This work could help to prevent pregnancy complications and stillbirth.
    Homing peptides: targeting drugs to the placenta

  • Stillbirth and fetal free haemoglobin

    Researchers supported by Tommy’s have found that the substance that usually carries oxygen around our blood may have harmful effects on the baby when it escapes from red blood cells.
    Stillbirth and fetal free haemoglobin

  • ReMIT-2 – a feasibility study for spotting the early signs of complications

    We need better ways to spot the early signs of pregnancy complications. The ReMIT-2 study laid the foundations for a large clinical trial of a blood test which could predict which women need urgent care to prevent stillbirth.
    ReMIT-2 – a feasibility study for spotting the early signs of complications

  • Can steroid injections improve blood flow to babies at risk of stillbirth?

    Finding out whether steroids can improve the blood flow through the placenta
    Can steroid injections improve blood flow to babies at risk of stillbirth?

Tommy’s news and views